Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
MIAMI, March 03, 2017 -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced that it will host a conference call to update investors on the Company’s product commercialization and drug development progress on Thursday, March 9, 2017 at 10:30 a.m. Eastern Time (ET).
|
|||
The conference call will be available to interested parties by dialing 1-877-883-0383 from the U.S. or 1-412-902-6506 from international locations, participant entry number for all 9649925.
A replay of the conference call will be available beginning on Tuesday, March 14, 2017 through Tuesday, March 21, 2017, by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the replay access code 10102781. After Tuesday, March 21, 2017, the replay of the call will be available on the Company’s website at www.fhcinvestor.com.
About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway. The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipes, which are a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
- The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business. This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.
More information about The Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org. For corporate and investor-related information about the Company, please visit www.FHCinvestor.com.
Contact: Kevin Gilbert: 312-366-2633
